Celsion Receives Fast Track Designation For ThermoDox® Development Program To Treat Primary Liver Cancer
Celsion Receives Fast Track Designation For ThermoDox® Development Program To Treat Primary Liver Cancer
Celsion Corporation (Nasdaq: CLSN ), a leading oncology drug development company, today announced that the U.S. Food and Drug Administration (FDA) has designated the HEAT Study of its investigational drug, ThermoDox®, in combination with radiofrequency ablation (RFA), as a Fast Track Development Program.
Read more on PharmaceuticalOnline
Categories: Breast Cancer Risks Tags: cancer, Celsion, Designation, Development, fast, liver, Primary, program, receives, ThermoDox®, track, treat